Skip to main content

Regulation of Glycolysis in Head and Neck Cancer

Part of the Advances in Experimental Medicine and Biology book series (AEMB,volume 1280)

Abstract

Head and neck squamous cell carcinoma (HNSCC) glycolysis is an important factor for the advancement of the disease and metastasis. Upregulation of glycolysis leads to decreased sensitivity to chemotherapy and radiation. HNSCC cells maintain constitutive glycolytic flux generating metabolic intermediates for the synthesis of amino acids, nucleotides, and fats for cell survival and disease progression. There are several pathways such as PI3K/Akt, EGFR, and JAK-STAT that contribute a major role in metabolic alteration in HNSCC. Recent studies have demonstrated that cancer-associated fibroblasts abundant in the HNSCC tumor microenvironment play a major role in HNSCC metabolic alteration via hepatocyte growth factor (HGF)/c-Met cross signaling. Despite therapeutic advancement, HNSCC lacks broad range of therapeutic interventions for the treatment of the disease. Thus, understanding the different key players involved in glucose metabolism and targeting them would lead to the development of novel drugs for the treatment of HNSCC.

Keywords

  • HNSCC
  • Glycolysis
  • HK-II
  • GLUT-1
  • LDH-A
  • MCT
  • PI3K
  • Akt
  • HGF/c-MET
  • TAFs

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bray, F., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21492.

  2. Franceschi, S., et al. (1999). Comparison of the effect of smoking and alcohol drinking between oral and pharyngeal cancer. International Journal of Cancer. https://doi.org/10.1002/(SICI)1097-0215(19990924)83:1<1::AID-IJC1>3.0.CO;2-8.

  3. Sanderson, R. J., & Ironside, J. A. D. (2002). Squamous cell carcinomas of the head and neck. BMJ (Clinical Research ed.), 325(7368), 822–827. https://doi.org/10.1136/bmj.325.7368.822.

    CrossRef  CAS  Google Scholar 

  4. Marur, S., et al. (2010). HPV-associated head and neck cancer: A virus-related cancer epidemic. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(10)70017-6.

  5. Kumar, D., et al. (2018). Cancer-associated fibroblasts drive glycolysis in a targetable signaling loop implicated in head and neck squamous cell carcinoma progression. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-17-1076.

  6. Warburg, O. (2004). The Metabolism of tumors in the body. The Journal of General Physiology. https://doi.org/10.1085/jgp.8.6.519.

  7. Liu, X., et al. (2010). Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis. Oncogene. https://doi.org/10.1038/onc.2009.332.

  8. Brown, R. S., et al. (2002). Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nuclear Medicine and Biology. https://doi.org/10.1016/S0969-8051(02)00288-3.

  9. Semenza, G. L., et al. (1994). Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Journal of Biological Chemistry.

    Google Scholar 

  10. Lunt, S. Y., & Vander Heiden, M. G. (2011). Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annual Review of Cell and Developmental Biology. https://doi.org/10.1146/annurev-cellbio-092910-154237.

  11. Pfeiffer, T., Schuster, S., & Bonhoeffer, S. (2001). Cooperation and competition in the evolution of ATP-producing pathways. Science. https://doi.org/10.1126/science.1058079.

  12. Seagroves, T. N., et al. (2001). Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Molecular and Cellular Biology. https://doi.org/10.1128/MCB.21.10.3436-3444.2001.

  13. Ayala, A., Fabregat, I., & Machado, A. (1991). The role of NADPH in the regulation of glucose-6-phosphate and 6-phosphogluconate dehydrogenases in rat adipose tissue. Molecular and Cellular Biochemistry, 105, 1–5.

    CrossRef  CAS  Google Scholar 

  14. Reitzer, L. J., Wice, B. M., & Kennell, D. (1979). Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. Journal of Biological Chemistry. https://doi.org/10.1007/s00125-007-0708-y.

  15. Suh, Y., et al. (2014). Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death & Disease. https://doi.org/10.1038/cddis.2013.548.

  16. Tweardy, D. J. (1993). Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Research.

    Google Scholar 

  17. Sok, J. C., et al. (2006). Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-06-0913.

  18. Makinoshima, H., et al. (2014). Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.M114.575464.

  19. Wanka, C., Steinbach, J. P., & Rieger, J. (2012). Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.M112.384578.

  20. Brennan, J. A., et al. (2002). Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. New England Journal of Medicine. https://doi.org/10.1056/nejm199503163321104.

  21. Poeta, M. L., et al. (2007). TP53 mutations and survival in squamous-cell carcinoma of the head and neck. New England Journal of Medicine. https://doi.org/10.1056/nejmoa073770.

  22. Agrawal, N., et al. (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. https://doi.org/10.1126/science.1206923.

  23. Landor, S. K.-J., et al. (2011). Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1104943108.

  24. Rathmell, J. C., et al. (2003). Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Molecular and Cellular Biology.

    Google Scholar 

  25. Elstrom, R. L., et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-03-2904.

  26. Bos, J. L. (1989). Ras oncogenes in human cancer: A review. Cancer Research.

    Google Scholar 

  27. Seiwert, T. Y., Beck, T. N., & Salgia, R. (2014). The role of HGF/c-MET in head and neck squamous cell carcinoma. In Molecular determinants of head and neck cancer. https://doi.org/10.1007/978-1-4614-8815-6_5.

    CrossRef  Google Scholar 

  28. Knowles, L. M., et al. (2009). HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-08-3252.

  29. Sierra, J. R., & Tsao, M. S. (2011). c-MET as a potential therapeutic target and biomarker in cancer. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/1758834011422557.

  30. Grandis, J. R., et al. (2002). Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.97.8.4227.

  31. Sen, M., et al. (2012). First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: Implications for cancer therapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-12-0191.

  32. Curry, J. M., et al. (2014). Tumor microenvironment in head and neck squamous cell carcinoma. Seminars in Oncology. https://doi.org/10.1053/j.seminoncol.2014.03.003.

  33. Warburg, O. (2004). The Metabolism of tumors in the body. The Journal of General Physiology. https://doi.org/10.1085/jgp.8.6.519.

  34. Sandulache, V. C., et al. (2011). Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer. https://doi.org/10.1002/cncr.25868.

  35. Fantin, V. R., St-Pierre, J., & Leder, P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. https://doi.org/10.1016/j.ccr.2006.04.023.

  36. Shestov, A. A., et al. (2014). Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. eLife. https://doi.org/10.7554/eLife.03342.

  37. Zhao, Y., Butler, E. B., & Tan, M. (2013). Targeting cellular metabolism to improve cancer therapeutics. Cell Death and Disease. https://doi.org/10.1038/cddis.2013.60.

  38. Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007). Hypoxia signalling controls metabolic demand. Current Opinion in Cell Biology. https://doi.org/10.1016/j.ceb.2007.02.003.

  39. Ebert, B. L., Firth, J. D., & Ratcliffe, P. J. (1995). Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.270.49.29083.

  40. Minchenko, O., Opentanova, I., & J, C. (2003). Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Letters, 554(3), 264–270.

    CrossRef  CAS  Google Scholar 

  41. Mueckler, M., et al. (1985). Sequence and structure of a human glucose transporter. Science. https://doi.org/10.1126/science.3839598.

  42. Kunkel, M., et al. (2003). Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. https://doi.org/10.1002/cncr.11159.

  43. Osawa, H., et al. (1995). Regulation of hexokinase II gene transcription and glucose phosphorylation by catecholamines, cyclic AMP, and insulin. Diabetes. https://doi.org/10.2337/diab.44.12.1426.

  44. Yamada, T., Uchida, M., Kwang-Lee, K., Kitamura, N., Yoshimura, T., Sasabe, E., & Yamamoto, T. (2012). Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 113(4), 464–471.

    CrossRef  Google Scholar 

  45. Yao, J., Liu, J., & Zhao, W. (2018). By blocking hexokinase-2 phosphorylation, limonin suppresses tumor glycolysis and induces cell apoptosis in hepatocellular carcinoma. Onco Targets and Therapy. https://doi.org/10.2147/OTT.S165220.

  46. Blatt, S., et al. (2016). Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years. Clinical Oral Investigations. https://doi.org/10.1007/s00784-015-1699-6.

  47. Flores, A., et al. (2019). Increased lactate dehydrogenase activity is dispensable in squamous carcinoma cells of origin. Nature Communications. https://doi.org/10.1038/s41467-018-07857-9.

  48. Le, A., et al. (2010). Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0914433107.

  49. Tamada, M., Suematsu, M., & Saya, H. (2012). Pyruvate kinase M2: Multiple faces for conferring benefits on cancer cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-12-0859.

  50. Kurihara-Shimomura, M., et al. (2018). The multifarious functions of pyruvate kinase M2 in oral cancer cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms19102907.

  51. Pinheiro, C., et al. (2012). Role of monocarboxylate transporters in human cancers: State of the art. Journal of Bioenergetics and Biomembranes. https://doi.org/10.1007/s10863-012-9428-1.

  52. Halestrap, A. P., & Meredith, D. (2004). The SLC16 gene family – From monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Archiv European Journal of Physiology. https://doi.org/10.1007/s00424-003-1067-2.

  53. Ullah, M. S., Davies, A. J., & Halestrap, A. P. (2006). The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.M511397200.

  54. Halestrap, A. P., & Wilson, M. C. (2012). The monocarboxylate transporter family-Role and regulation. IUBMB Life. https://doi.org/10.1002/iub.572.

  55. Amornphimoltham, P., et al. (2004). Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: A potential target for UCN-01. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-03-0249.

  56. Kim, D. I., Lim, S. K., & Park, M. (2007b). The involvement of phosphatidylinositol 3-kinase/Akt signaling in high glucose-induced downregulation of GLUT-1 expression in ARPE cells. Life Sciences, 80, 626–632.

    CrossRef  CAS  Google Scholar 

  57. Deprez, J., et al. (1997). Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.272.28.17269.

  58. Agnihotri, S., & Zadeh, G. (2016). Metabolic reprogramming in glioblastoma: The influence of cancer metabolism on epigenetics and unanswered questions. Neuro-Oncology. https://doi.org/10.1093/neuonc/nov125.

  59. Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C. A., Aldape, K., Cantley, L. C., & Z, L. (n.d.). ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nature Cell Biology, 15(1) 124, pp. 1295–1304.

    Google Scholar 

  60. Grandis, J. R., et al. (1998). Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/90.11.824.

  61. Babic, I., et al. (2013). EGFR mutation-induced alternative splicing of max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. https://doi.org/10.1016/j.cmet.2013.04.013.

  62. Huang, L. E., et al. (2002). Regulation of hypoxia-inducible factor 1 is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.95.14.7987.

  63. Kumar, R., Juillerat-Jeanneret, L., & Golshayan, D. (2016). Notch antagonists: Potential modulators of cancer and inflammatory diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5b01516.

  64. Sun, W., et al. (2014). Activation of the NOTCH pathway in head and neck cancer. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-13-1259.

  65. Bi, P., & Kuang, S. (2015). Notch signaling as a novel regulator of metabolism. Trends in Endocrinology and Metabolism. https://doi.org/10.1016/j.tem.2015.02.006.

  66. Bottaro, D. P., et al. (1991). Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. https://doi.org/10.1126/science.1846706.

  67. Park, M., et al. (2006). Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.84.18.6379.

  68. Kumar, D., et al. (2015). Mitigation of tumor-associated fibroblast-facilitated head and neck cancer progression with anti-hepatocyte growth factor antibody ficlatuzumab. JAMA Otolaryngology – Head and Neck Surgery. https://doi.org/10.1001/jamaoto.2015.2381.

  69. Kim, C. H., et al. (2007a). Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-006-9320-5.

  70. Koontongkaew, S., Amornphimoltham, P., & Yapong, B. (2009). Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells. Cell Biology International. https://doi.org/10.1016/j.cellbi.2008.10.009.

  71. Lui, V. W. Y., et al. (2011). Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene. https://doi.org/10.1038/onc.2010.490.

  72. Korneev, K. V., et al. (2017). TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine. https://doi.org/10.1016/j.cyto.2016.01.021.

  73. Joyce, J. A., & Fearon, D. T. (2015). T cell exclusion, immune privilege, and the tumor microenvironment. Science. https://doi.org/10.1126/science.aaa6204.

  74. Spill, F., et al. (2016). Impact of the physical microenvironment on tumor progression and metastasis. Current Opinion in Biotechnology. https://doi.org/10.1016/j.copbio.2016.02.007.

  75. Desmoulière, A., Guyot, C., & Gabbiani, G. (2004). The stroma reaction myofibroblast: A key player in the control of tumor cell behavior. International Journal of Developmental Biology. https://doi.org/10.1387/ijdb.041802ad.

  76. Curry, J. M., et al. (2013). Cancer metabolism, stemness and tumor recurrence : MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle. https://doi.org/10.4161/cc.24092.

  77. Partridge, M., et al. (1996). Expression of bFGF, KGF and FGF receptors on normal oral mucosa and SCC. European Journal of Cancer Part B: Oral Oncology. https://doi.org/10.1016/0964-1955(95)00056-9.

  78. Hitosugi, T., et al. (2011). Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Molecular Cell. https://doi.org/10.1016/j.molcel.2011.10.015.

  79. Vermorken, J. B., et al. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa0802656.

  80. Bonner, J. A., et al. (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(09)70311-0.

  81. Singh, R. P., et al. (2005). Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-κB: Implications for angioprevention and antiangiogenic therapy. Oncogene. https://doi.org/10.1038/sj.onc.1208276.

  82. Flaig, T. W., et al. (2010). A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. https://doi.org/10.1002/pros.21118.

  83. Pelicano, H., et al. (2006). Glycolysis inhibition for anticancer treatment. Oncogene. https://doi.org/10.1038/sj.onc.1209597.

  84. Dwarakarnath, B. S., & Jain, V. (2009). Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncology. https://doi.org/10.2217/fon.09.44.

  85. Whitehouse, S., Cooper, R. H., & Randle, P. J. (2015). Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochemical Journal. https://doi.org/10.1042/bj1410761.

  86. Zhang, X., et al. (2014). Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nature Communications. https://doi.org/10.1038/ncomms4295.

  87. Lucido, C. T., Miskimins, W. K., & Vermeer, P. D. (2018). Propranolol promotes glucose dependence and synergizes with dichloroacetate for anti-cancer activity in HNSCC. Cancers. https://doi.org/10.3390/cancers10120476.

  88. Voigt, M., et al. (2015). Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia. https://doi.org/10.1593/neo.121242.

  89. Reddy, B. K. M., et al. (2014). Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncology. https://doi.org/10.1016/j.oraloncology.2013.11.008.

  90. Soulieres, D., Faivre, S. J., & R, M. (2017). BERIL-1: a phase II, placebo-controlled study of buparlisib (BKM120) Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): A randomised, double-blind, placebo-control. The Lancet Oncology, 18(3), 323–335.

    CrossRef  CAS  Google Scholar 

  91. Geiger, J. L., et al. (2016). Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head and Neck. https://doi.org/10.1002/hed.24501.

  92. Massarelli, E., Lin, H., Ginsberg, L. E., Tran, H. T., Lee, J. J., Canales, J. R., Blumenschein, M. D. W. G. R., Lu, C., Heymach, J. V., Kies, M. S., & Papadimitrakopoulou, V. (2015). Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology, 26(7), 1476–1480.

    CrossRef  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dhruv Kumar .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Raj, S., Kumar, A., Kumar, D. (2021). Regulation of Glycolysis in Head and Neck Cancer. In: Hu, S. (eds) Cancer Metabolomics. Advances in Experimental Medicine and Biology, vol 1280. Springer, Cham. https://doi.org/10.1007/978-3-030-51652-9_15

Download citation